To conclude, our findings highlight the therapeutic potential of combining CSF1/CSF1R pathway targeting agents with neoepitope targeting vaccines to further modulate anti-tumor immune responses in the tumor microenvironment. This evidence concerns the gene CSF1R and neoplasm.